Exhibit 99.1 Press Release HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer — NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in refractory metastatic colorectal cancer (0.66 HR), consistent with the 35% reduction in the risk of death ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Mark Lee - SVP Corporate Finance and Development Weiguo Su - CEO and Chief Scientific Officer Hong Chen - Chief Commercial Officer Johnny Cheng - CFO Karen Atkin - COO Mike Shi - Chief Medical Officer and Head of R&D Conference Call Participants Kelly Shi - Jefferies Louise Chen - Cantor Alec Stranahan - Bank of America Merrill Lynch Yang Huang - Credit Suisse Mike Mitchell - Panmure Gor ...

Exhibit 99.1 HUTCHMED Reports 2022 Full Year Results and Provides Business Updates Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE, SULANDA and ORPATHYSalongside clinical and strategic progress Company to Host Annual Results Call & Webcast Today at 9 p.m. HKT ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR Date of event requiring this shell comp ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Weiguo Su - Executive Director, Chief Executive Officer and Chief Scientific Officer Johnny Cheng - Executive Director and Chief Financial Officer Marek Kania - Executive Vice President, Managing Director and Chief Medical Officer, International Karen Atkin - Executive Vice President and Chief Operating Officer Hong Chen - Chief Commercial Officer of China, Senior Vice President and Chief Co ...